Clinical Trials

Immune Pharmaceuticals Inc., will announce on Monday, February 20th, 2017 at the Acute Leukemia XVI symposium in Munich, Germany that it will be launching REMAIN™, an international…
Read More...

Otsuka Pharmaceutical Co., Ltd. and Lundbeck Canada announce that Health Canada issued a Notice of Compliance for REXULTI (brexpiprazole) for the treatment of schizophrenia in adults.…
Read More...

Dauntless Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development of specialty therapeutics announced the initiation of a Phase 1 clinical study to…
Read More...

Imprimis Pharmaceuticals, Inc.an ophthalmology-focused pharmaceutical company announced that it has begun shipping its core sterile ophthalmic medications to select customers from its…
Read More...

Vyome Biosciences, a clinical-stage specialty pharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes, announced top-line data from its…
Read More...

Amgen announced that the U.S. Food and Drug Administration (FDA) has approved Parsabiv™ (etelcalcetide) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with…
Read More...

GW Pharmaceuticals has unveiled positive top-line results from an exploratory Phase 2 placebo-controlled clinical study of a combination of tetrahydrocannabinol (THC) and cannabidiol…
Read More...

Jazz Pharmaceuticals plc \announced that the first patient has been enrolled in a Phase 2 clinical study evaluating JZP-110, a selective dopamine and norepinephrine reuptake inhibitor,…
Read More...

Quotient Clinical announces that it has acquired SeaView Research, expanding its operations into the USA. The acquisition combines Quotient and SeaView’s complementary customer…
Read More...

Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced that the U.S.…
Read More...

Strata Oncology announced an agreement with Epizyme to support patient identification and enrollment for Epizyme’s ongoing Phase 2 clinical trial of tazemetostat in patients with…
Read More...

Portola Pharmaceuticals, Inc.® (PTLA) announced that it has signed a $150 million royalty agreement with HealthCare Royalty Partners (HCR). Under the terms of the agreement, Portola…
Read More...

Lysogene announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to LYS-GM101, the company’s gene therapy drug candidate for treatment of GM1…
Read More...

Cocoon Biotech, Inc., is a biotechnology company focused on utilizing its silk protein-based drug delivery technology for the development of formulations to treat osteoarthritis and…
Read More...

HOPE BIOSCIENCES, INC. announced that it has acquired exclusive and worldwide rights to develop and commercialize HOPE 777, a unique MERTK/AXL/pan-c-MET tyrosine kinase inhibitor…
Read More...

Meridian Laboratories, Inc., a Buffalo, IL based specialty-oncology drug development company, announced today that it has entered into a definitive agreement with Apobiologix, a part of…
Read More...

Abbott announced that US FDA (Food and Drug Administration) has granted authorization for RealTime ZIKA test, to detect Zika virus in whole Blood for emergency use. This is the first…
Read More...

GenSight Biologics, a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system,…
Read More...

Ipsen announces that it has signed an agreement to take an equity stake in Akkadeas Pharma with an option to take control of the company in the future. Akkadeas Pharma is a…
Read More...

Noxopharm announces that it has entered into a research agreement with the University of Hong Kong to conduct research into the use of the drug idronoxil (NOX66 active ingredient) to…
Read More...